Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | ADH1B | P00325 | 2/20 | 0.46 |
| ▸ | ADH1C | P00326 | 2/20 | 0.46 |
| ▸ | ADH1A | P07327 | 2/20 | 0.46 |
| ▸ | ADH4 | P08319 | 2/20 | 0.46 |
| ▸ | ADH7 | P40394 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1751775 | 1.00 | FAAH (0.46) | FAAHADH1BADH1CADH1AADH4 | |
| SCHEMBL8637402 | 1.00 | FAAH (0.46) | FAAHADH1BADH1CADH1AADH4 | |
| SCHEMBL7522857 | 1.00 | FAAH (0.46) | FAAHADH1BADH1CADH1AADH4 | |
| SCHEMBL4910687 | 1.00 | FAAH (0.46) | FAAHADH1BADH1CADH1AADH4 | |
| SCHEMBL667726 | 0.98 | RELA (0.43) | FAAHADH1BADH1CADH1AADH4 | |
| SCHEMBL424438 | 0.91 | HPGD (0.43) | FAAHADH1BADH1CADH1AADH4 | |
| SCHEMBL8520694 | 0.87 | RELA (0.37) | FAAHADH1BADH1CADH1AADH4 | |
| SCHEMBL8560726 | 0.83 | FAAH (0.46) | FAAHRELACA2MEN1ALDH1A1 | |
| SCHEMBL423937 | 0.81 | — | — | |
| SCHEMBL11755607 | 0.81 | FAAH (0.45) | FAAHRELACA2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7867992-B2 | such as 1-Cyclopropyl-N-(2,4-dichlorobenzyl)-6-fluoro-8-methoxy-7-[3-methyl-4-(2-{[(methylamino)carbonyl]amino}-2-oxoethyl)piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxamide, used for the treatment and/or prophylaxis of viral diseases or infections, particularly against cytomegaloviruses | AICURIS GMBH & CO. KG (DE) | 2011-01-11 | — | — | US | disclosed |
| US-20070293478-A1 | Substituted quinolones | BAYER HEALTHCARE AG (DE) | 2007-12-20 | — | — | US | disclosed |
| EP-1768973-B1 | SUBSTITUTED QUINOLONES | AICURIS GMBH & CO KG (DE) | 2007-12-05 | — | — | EP | disclosed |
| US-7285572-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7205083-B2 | Recording material | FUJIFILM CORPORATION (JP) | 2007-04-17 | — | — | US | disclosed |
| EP-1768973-A1 | SUBSTITUTED QUINOLONES | AiCuris GmbH & Co. KG (DE) | 2007-04-04 | — | — | EP | disclosed |
| US-7115647-B2 | Method of inhibiting neoplastic cells with indole derivatives | OSI PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060135572-A1 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1630157-A1 | CaSR ANTAGONIST | JAPAN TOBACCO INC. (JP) | 2006-03-01 | — | — | EP | disclosed |
| WO-2006008046-A1 | SUBSTITUTED QUINOLONES | AICURIS GMBH & CO. KG (DE) | 2006-01-26 | — | — | WO | disclosed |
| US-5514701-A | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-07 | — | — | US | disclosed |
| EP-0648743-A1 | PROCESS FOR PRODUCING PYRROLIDINE DERIVATIVE AND SALT THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-04-19 | — | — | EP | disclosed |
| US-5264453-A | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-11-23 | — | — | US | disclosed |
| EP-0552646-A1 | Silver halide photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1993-07-28 | — | — | EP | disclosed |
| EP-0289911-B1 | PYRROLIDINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-16 | — | — | EP | disclosed |
| WO-1993006108-A1 | PYRROLOBENZOXAZINE DERIVATIVES AS 5-HT AGONISTS AND ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-04-01 | — | — | WO | disclosed |
| US-5130323-A | PYRROLIDINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-07-14 | — | — | US | disclosed |
| EP-0367130-A2 | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-09 | — | — | EP | disclosed |
| US-4916152-A | THROMBOXANE A2 ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-10 | — | — | US | disclosed |
| EP-0289911-A2 | Pyrrolidine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135572-A1 | CaSR antagonist | CASR, CALCR, CALCRL | FAAH 3179/4885ADH1B 4132/4885ADH1C 4212/4885 |
| US-20070293478-A1 | Substituted quinolones | IRF3, TPMT, NQO2 | FAAH 3549/4885ADH1B 1783/4885ADH1C 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.